Notícias

European Commission approves Amgen’s IMDYLLTRA for extensive stage small cell lung cancer, opening a new targeted immunotherapy option for patients in the region. FDA proposes withdrawing Tavneos from the U.S. market over data integrity and safety concerns, including reports of patient deaths. Amgen, NasdaqGS:AMGN, initiates an independent review with the Duke Clinical Research Institute to respond to the FDA’s findings and protect its autoimmune franchise. For investors watching...

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In […]

Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

Amgen brings in Duke to review Tavneos data as FDA questions approval and safety concerns.

New cancer therapies may help fund dividend growth.

Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data from the VESALIUS-CV trial at the American Diabetes Association’s 86th Scientific Sessions, demonstrating that Repatha significantly reduces cardiovascular risk in patients with high-risk diabetes. In a subgroup of 6,002 patients with […]

Is AMGN a good stock to buy? We came across a bullish thesis on Amgen Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc.’s share was trading at $344.57 as of June 9th. AMGN’s trailing and forward P/E were 23.98 and 15.48 respectively according to Yahoo Finance. Amgen […]

SpaceX initiated, Intel upgraded: Wall Street's top analyst calls

Wall Street looked set to rebound strongly on Thursday, before Donald Trump published a warning that the US will conduct strikes on Iran "very hard tonight". He added in a social media post that Washington "will be taking Kharg Island" and other oil infrastructure sites to "assume total...

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.

In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

Nvidia, Visa and Microsoft lead the list of Wall Street's top Dow Jones stocks to buy now. Some other names might surprise you.

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

Investors may be asking whether Amgen's share price still offers value at current levels, or if most of the opportunity is already reflected in the price. Amgen's stock last closed at US$345.73, with returns of 5.3% over 7 days, 4.2% over 30 days, 5.5% year to date, 21.4% over 1 year, 70.8% over 3 years, and 68.7% over 5 years. Recent attention on Amgen has focused on its position in large cap biotechnology and how market participants are evaluating the balance between its growth prospects...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

With a net profit margin of 20.96%, Amgen Inc. (NASDAQ:AMGN) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. On June 5, Goldman Sachs lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $389 from $425. It reiterated a Buy rating on the stock. The firm adjusted its model after Amgen disclosed […]

More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.

Stock Market Today: The Dow Jones index rose Monday on Trump's latest Iran comments. Marvell stock surged on news that it'll join the S&P 500..

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

This new ranking also showcases tech giants Alphabet, Microsoft, Meta and Cisco, propelled by high scores for innovation, financial strength and AI readiness

The oldest stock index in the world is suffering from a severe case of split personality. This internal friction has triggered a mechanical phenomenon, the likes of which I cannot recall, at least to this degree.

Investors looking for the best tech ETF might be disappointed to discover that a lot of the Invesco QQQ ETF's portfolio isn't actually tech.

The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short ... SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.

Amgen stock snapshot and recent performance Amgen (AMGN) is drawing attention after recent price moves, with the stock last closing at US$349.58. Over the past month it gained about 5.6%, while over the past 3 months it declined roughly 5.4%. See our latest analysis for Amgen. The recent 1-day share price return of 1.15% and 7-day return of 3.8% build on a 30-day share price gain of 5.6%, while the 1-year total shareholder return of 24% and 3-year total shareholder return of about 75% point...

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

Amgen Inc. (NASDAQ:AMGN) is one of the best cheap stocks to buy for beginners. Amgen Inc. (NASDAQ:AMGN) announced on June 1 that the European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for the treatment of adults with extensive-stage small cell lung cancer who require systemic therapy following disease progression on or after first-line […]

Quantinuum’s IPO grabbed headlines, but its first trading day showed both excitement and caution. How can investors approach QNT stock after its Wall Street debut?